Cargando…

Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination

This study aimed to determine the population pharmacokinetic (Pop PK) parameters of cefazolin administered prophylactically at 25 mg/kg intravenously (IV) 30 min before surgery in a canine population of 78 dogs and assess whether covariates, such as sex, age, body weight (BW), breed, health status,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cagnardi, Petra, Di Cesare, Federica, Toutain, Pierre-Louis, Bousquet-Mélou, Alain, Ravasio, Giuliano, Villa, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190795/ https://www.ncbi.nlm.nih.gov/pubmed/30356800 http://dx.doi.org/10.3389/fphar.2018.01137

Ejemplares similares

A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients
por: Bousquet-Mélou, Alain, et al.
Publicado: (2021)

Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses
por: Di Cesare, Federica, et al.
Publicado: (2023)

Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses
por: Kuroda, Taisuke, et al.
Publicado: (2021)

En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach
por: Toutain, Pierre-Louis, et al.
Publicado: (2017)

Pharmacokinetic–pharmacodynamic cutoff values for benzylpenicillin in horses to support the establishment of clinical breakpoints for benzylpenicillin antimicrobial susceptibility testing in horses
por: Lallemand, Elodie A., et al.
Publicado: (2023)

2238. Effect of Cefazolin Breakpoint Update in Susceptibility Reports on Antimicrobial Use
por: Buckley, Valerie, et al.
Publicado: (2023)

Dexmedetomidine and ketamine simultaneous administration in tigers (Panthera tigris): pharmacokinetics and clinical effects
por: Di Cesare, Federica, et al.
Publicado: (2020)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients
por: Schmitz, Michael L., et al.
Publicado: (2020)

Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time
por: Baklouti, Sarah, et al.
Publicado: (2021)

Interpreting Bisphenol A Absorption in the Canine Oral Cavity: Gayrard et al. Respond
por: Gayrard, Véronique, et al.
Publicado: (2013)

Population Pharmacokinetics of Prophylactic Cefazolin in Cardiac Surgery with Standard and Minimally Invasive Extracorporeal Circulation
por: Šantavý, Petr, et al.
Publicado: (2022)

Cefazolin Pharmacokinetics in Premature Infants
por: Balevic, Stephen J., et al.
Publicado: (2019)

Oral Transmucosal or Intramuscular Administration of Dexmedetomidine–Methadone Combination in Dogs: Sedative and Physiological Effects
por: Gioeni, Daniela, et al.
Publicado: (2020)

Population Pharmacokinetics of Intravenous Amoxicillin Combined With Clavulanic Acid in Healthy and Critically Ill Dogs
por: Vegas Cómitre, Maria D., et al.
Publicado: (2021)

Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital
por: Chastain, Daniel B., et al.
Publicado: (2017)

Prophylactic Cefazolin Dosing in Obesity—a Systematic Review
por: Coates, Matthew, et al.
Publicado: (2022)

Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish
por: Chen, Bo, et al.
Publicado: (2017)

Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms
por: Ferran, Aude A., et al.
Publicado: (2016)

VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle
por: Toutain, Pierre-Louis, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Ceftriaxone and cefazolin attenuate the cue-primed reinstatement of alcohol-seeking
por: Weiland, Ana, et al.
Publicado: (2015)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Veterinary Medicine Needs New Green Antimicrobial Drugs
por: Toutain, Pierre-Louis, et al.
Publicado: (2016)

Implementing Precision Antimicrobial Therapy for the Treatment of Bovine Respiratory Disease: Current Limitations and Perspectives
por: Lhermie, Guillaume, et al.
Publicado: (2017)

Prophylactic cefazolin in amnioinfusions administered for meconium-stained amniotic fluid.
por: Edwards, R K, et al.
Publicado: (1999)

Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies
por: Lhermie, Guillaume, et al.
Publicado: (2015)

Use of dexmedetomidine repeated subcutaneous administration for balanced anaesthesia in horses
por: Rabbogliatti, Vanessa, et al.
Publicado: (2022)

Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice
por: Vasseur, Maleck V., et al.
Publicado: (2017)

Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?
por: Concordet, Didier, et al.
Publicado: (2019)

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
por: Liu, Yongge, et al.
Publicado: (2023)

Population pharmacokinetic model of cefazolin in total hip arthroplasty
por: Lanoiselée, J., et al.
Publicado: (2021)

Dynamic interactions between cephalexin and macrophages on different Staphylococcus aureus inoculum sizes: a tripartite in vitro model
por: Lallemand, Elodie Anne, et al.
Publicado: (2021)

CEFAZOLIN PROPHYLACTIC EFFICACY ON PROSTHETIC JOINT INFECTION AFTER PRIMARY HIP ARTHROPLASTY
por: Kobayashi, Shunsuke, et al.
Publicado: (2022)

Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Nicolas: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Coste et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Concordet, Didier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_572fe5h8c1ccir8cfmkv2fs5hs